文献速递肝病

肝硬化中抗生素相关微生物群组成与功能破坏可经粪菌移植恢复

Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.
PubMed 文献 · Hepatology · 2018-09-20

在FDA监管的1期临床安全性试验中,失代偿期肝硬化患者随机接受标准治疗(无抗生素/粪菌移植)或5天广谱抗生素后接受富含毛螺菌科和瘤胃球菌科的供体粪菌移植;粪菌移植耐受良好,抗生素后微生物多样性及功能改变在粪菌移植后15天恢复至基线水平,标准治疗组无变化。

要点

  • 在失代偿期肝硬化患者中,粪菌移植耐受良好。
  • 广谱抗生素后微生物多样性及固有分类群相对丰度降低,粪便短链脂肪酸和胆汁酸谱改变。
  • 粪菌移植后15天上述参数恢复至与基线统计学相似,标准治疗组无变化。

核心结论

  • 在接受乳果糖和利福昔明的晚期肝硬化患者中,粪菌移植恢复了抗生素相关的微生物多样性和功能破坏。

研究设计与样本

  • 在FDA监管的1期临床安全性试验中,失代偿期肝硬化患者接受标准治疗(乳果糖和利福昔明),随机分为标准治疗组(无抗生素/粪菌移植)或5天广谱抗生素后接受来自富含毛螺菌科和瘤胃球菌科供体的粪菌移植。
  • 在基线、抗生素后和粪菌移植后15天分析微生物组成(多样性、科水平相对丰度)、功能(粪便胆汁酸解结合、7α-脱羟基化、短链脂肪酸)以及毛螺菌科、瘤胃球菌科与临床变量之间的相关性。

主要发现

  • 粪菌移植耐受良好。
  • 抗生素后,微生物多样性和固有分类群相对丰度降低,并与粪便短链脂肪酸和胆汁酸谱改变相关。
  • 相关性连接从基线的有益变为抗生素后的负性。
  • 所有上述参数在粪菌移植后与基线水平统计学相似。
  • 标准治疗组未见变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis. In a Food and Drug Administration-monitored phase 1 clinical safety trial, patients with decompensated cirrhosis on standard therapies (lactulose and rifaximin) were randomized to standard-of-care (SOC, no antibiotics/FMT) or 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae. Microbial composition (diversity, family-level relative abundances), function (fecal bile acid [BA] deconjugation, 7α-dehydroxylation, short-chain fatty acids [SCFAs]), and correlations between Lachnospiraceae, Ruminococcaceae, and clinical variables were analyzed at baseline, postantibiotics, and 15 days post-FMT. FMT was well tolerated. Postantibiotics, there was a reduced microbial diversity and autochthonous taxa relative abundance. This was associated with an altered fecal SCFA and BA profile. Correlation linkage changes from beneficial at baseline to negative after antibiotics. All of these parameters became statistically similar post-FMT to baseline levels. No changes were seen in the SOC group. CONCLUSION: In patients with advanced cirrhosis on lactulose and rifaximin, FMT restored antibiotic-associated disruption in microbial diversity and function. (Hepatology 2018; 00:000-000).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant. Hepatology. 2018. PMID: 29665102. doi:10.1002/hep.30037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。